- Report
- May 2024
- 200 Pages
Global
From €3681EUR$4,150USD£3,193GBP
- Report
- October 2023
- 145 Pages
Global
From €2794EUR$3,150USD£2,423GBP
- Report
- October 2023
- 145 Pages
Global
From €2794EUR$3,150USD£2,423GBP
- Report
- September 2024
- 82 Pages
Japan
From €3104EUR$3,500USD£2,693GBP
- Report
- September 2024
- 82 Pages
Japan
From €3104EUR$3,500USD£2,693GBP
- Report
- August 2024
- 80 Pages
Japan
From €3104EUR$3,500USD£2,693GBP
- Report
- April 2024
- 190 Pages
Global
From €3991EUR$4,500USD£3,462GBP
- Report
- October 2023
- 190 Pages
Global
From €3991EUR$4,500USD£3,462GBP
- Report
- June 2023
- 112 Pages
Global
From €3991EUR$4,500USD£3,462GBP
- Report
- May 2024
- 185 Pages
Global
From €3991EUR$4,500USD£3,462GBP
- Report
- March 2024
- 150 Pages
Global
From €3947EUR$4,450USD£3,423GBP
- Report
- August 2022
- 111 Pages
Global
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2022
- 110 Pages
Global
From €4213EUR$4,750USD£3,654GBP
- Report
- June 2022
- 120 Pages
Global
From €4213EUR$4,750USD£3,654GBP
- Report
- April 2023
- 115 Pages
Global
From €4213EUR$4,750USD£3,654GBP
- Report
- July 2024
- 185 Pages
Global
From €2217EUR$2,500USD£1,923GBP
- Report
- May 2024
- 174 Pages
Global
From €2217EUR$2,500USD£1,923GBP
- Report
- May 2022
- 70 Pages
Global
From €2217EUR$2,500USD£1,923GBP
- Report
- October 2021
- 288 Pages
Global
From €3193EUR$3,600USD£2,769GBP
- Report
- February 2024
- 140 Pages
Global
From €4407EUR$4,969USD£3,823GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more